UB Paderborn / Katalog / Suche / in CDI

Anacetrapib as Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolaemia (REALIZE): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study

Journal of vascular surgery, 2016-04, Vol.63 (4), p.1127-1128

2016

Volltextzugriff (PDF)

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background

Atherosclerosis, 2016-09, Vol.252, p.e231-e231

2016

Volltextzugriff (PDF)

Recombinant human apolipoprotein-a-i prebeta-HDL (cer-001) promotes reverse cholesterol transport and reduces carotid wall thickness in patients with genetically-determined low HDL

Atherosclerosis, 2014-08, Vol.235 (2), p.e14-e14

2014

Volltextzugriff (PDF)

Obicetrapib lowers LDL-C in patients on high intensity statins: Results from the rose trial (NCT04753606)

Atherosclerosis, 2022-08, Vol.355, p.11-12

2022

Volltextzugriff (PDF)

Identification, characteristics and management of adults with heterozygous Familial Hypercholesterolaemia in high and non-high income countries participating in the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Atherosclerosis, 2022-08, Vol.355, p.15-16

2022

Volltextzugriff (PDF)

Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial

Atherosclerosis, 2020-12, Vol.315, p.e8-e8

2020

Volltextzugriff (PDF)

The efficacy and safety of evinacumab in homozygous familial hypercholesterolaemia (HoFH) patients with little to no low-density lipoprotein receptor (LDLR) activity

Atherosclerosis, 2020-12, Vol.315, p.e8-e8

2020

Volltextzugriff (PDF)

Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia

Atherosclerosis, 2020-12, Vol.315, p.e7-e8

2020

Volltextzugriff (PDF)

Characteristics of adults with heterozygous familial hypercholesterolaemia stratified by gender: Preliminary analysis from the EAS FHSC global registry on over 36,000 cases of familial hypercholesterolaemia

Atherosclerosis, 2020-12, Vol.315, p.e13-e13

2020

Volltextzugriff (PDF)

Heterozygous familial hypercholesterolaemia in children: Preliminary analysis from the EAS FHSC global registry on over 7,900 children with familial hypercholesterolaemia

Atherosclerosis, 2020-12, Vol.315, p.e76-e76

2020

Volltextzugriff (PDF)

Ldl-C Lowering Among Patients With Ldl-C Above 4.9 Mmol/L And Features Suggesting A Genetic Vulnerability To Cardiovascular Disease: Analyses From The 4s Trial

Atherosclerosis, 2019-08, Vol.287, p.e6-e6

2019

Volltextzugriff (PDF)

ApoAI‐phosphatidylcholine infusion neutralizes the atherothrombotic effects of C‐reactive protein in humans

Journal of thrombosis and haemostasis, 2009-02, Vol.7 (2), p.347-354

2009

Volltextzugriff (PDF)

A compound heterozygote for lipoprotein lipase deficiency, Val69–>Leu and Gly188–>Glu: correlation between in vitro LPL activity and clinical expression

Journal of lipid research, 1994-03, Vol.35 (3), p.438-445

1994

Volltextzugriff (PDF)

A Major Insertion Accounts for a Significant Proportion of Mutations Underlying Human Lipoprotein Lipase Deficiency

Proceedings of the National Academy of Sciences - PNAS, 1989-02, Vol.86 (3), p.948-952

1989

Volltextzugriff (PDF)

217 IMPACT OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION ON NUCLEAR MAGNETIC RESONANCE DERIVED LIPOPROTEIN PARTICLE PARAMETERS

Atherosclerosis. Supplements, 2011-06, Vol.12 (1), p.48-48

2011

Volltextzugriff (PDF)

The spectrum of statin therapy in hyperlipidemic children

Seminars in vascular medicine, 2004-11, Vol.4 (4), p.313

2004

Volltextzugriff (PDF)

Allelic variation in the promoter region of the LDL receptor gene: analysis of an African-specific variant in the FP2 cis-acting regulatory element

Molecular and cellular probes, 2003-08, Vol.17 (4), p.175-181

2003

Volltextzugriff (PDF)

THE CARDIOVASCULAR SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR, RO4607381/JTT-705: PHASE II FINDINGS

Atherosclerosis. Supplements, 2008-05, Vol.9 (1), p.12-12

2008

Volltextzugriff (PDF)

176 ANTI-INFLAMMATORY EFFECTS OF A NOVEL INDUCER OF APOLIPOPROTEIN A-I SYNTHESIS: INSIGHTS FROM THE ASSERT STUDY

Atherosclerosis. Supplements, 2011-06, Vol.12 (1), p.39-39

2011

Volltextzugriff (PDF)

196 INCREASING CIRCULATING CONCENTRATION OF ALL HDL PARTICLE SUBCLASSES IN HYPER-RESPONDERS TO APOLIPOPROTEIN A-I INDUCTION: INSIGHTS FROM THE ASSERT STUDY

Atherosclerosis. Supplements, 2011-06, Vol.12 (1), p.44-44

2011

Volltextzugriff (PDF)

MS351 FOLLOW-UP OF CHILDREN AFTER POSITIVE GENETIC TESTING IN THE DUTCH NATIONAL SCREENING PROGRAM FOR FAMILIAL HYPERCHOLESTEROLEMIA

Atherosclerosis. Supplements, 2010-06, Vol.11 (2), p.180-180

2010

Volltextzugriff (PDF)

66 THE MOLECULAR BASIS OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA: ASSESSMENT IN A LARGE COHORT OF HYPERCHOLESTEROLEMIC CHILDREN

Atherosclerosis. Supplements, 2011-06, Vol.12 (1), p.16-16

2011

Volltextzugriff (PDF)

COMPARISON OF EFFECTS OF TORCETRAPIB AND RO4607381/JTT-705 ON BLOOD PRESSURE AND TISSUE EXPRESSION OF RENIN-ANGIOTENSIN SYSTEM-RELATED GENES IN RATS

Atherosclerosis. Supplements, 2008-05, Vol.9 (1), p.42-42

2008

Volltextzugriff (PDF)

PO23-733 INTENSIVE ATORVASTATIN THERAPY IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE: THE TNT STUDY

Atherosclerosis. Supplements, 2007-06, Vol.8 (1), p.195-195

2007

Volltextzugriff (PDF)

LB-OR-3 RELATIONSHIP BETWEEN HIGH-DENSITY LIPOPROTEIN PARTICLE SIZE AND CORONARY ARTERY DISEASE RISK IN THE EPIC-NORFOLK PROSPECTIVE STUDY

Atherosclerosis. Supplements, 2007-06, Vol.8 (1), p.227-227

2007

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Anacetrapib as Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolaemia (REALIZE): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background

Recombinant human apolipoprotein-a-i prebeta-HDL (cer-001) promotes reverse cholesterol transport and reduces carotid wall thickness in patients with genetically-determined low HDL

Obicetrapib lowers LDL-C in patients on high intensity statins: Results from the rose trial (NCT04753606)

Identification, characteristics and management of adults with heterozygous Familial Hypercholesterolaemia in high and non-high income countries participating in the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial

The efficacy and safety of evinacumab in homozygous familial hypercholesterolaemia (HoFH) patients with little to no low-density lipoprotein receptor (LDLR) activity

Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia

Characteristics of adults with heterozygous familial hypercholesterolaemia stratified by gender: Preliminary analysis from the EAS FHSC global registry on over 36,000 cases of familial hypercholesterolaemia

Heterozygous familial hypercholesterolaemia in children: Preliminary analysis from the EAS FHSC global registry on over 7,900 children with familial hypercholesterolaemia

Ldl-C Lowering Among Patients With Ldl-C Above 4.9 Mmol/L And Features Suggesting A Genetic Vulnerability To Cardiovascular Disease: Analyses From The 4s Trial

ApoAI‐phosphatidylcholine infusion neutralizes the atherothrombotic effects of C‐reactive protein in humans

A compound heterozygote for lipoprotein lipase deficiency, Val69–>Leu and Gly188–>Glu: correlation between in vitro LPL activity and clinical expression

A Major Insertion Accounts for a Significant Proportion of Mutations Underlying Human Lipoprotein Lipase Deficiency

217 IMPACT OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION ON NUCLEAR MAGNETIC RESONANCE DERIVED LIPOPROTEIN PARTICLE PARAMETERS

The spectrum of statin therapy in hyperlipidemic children

Allelic variation in the promoter region of the LDL receptor gene: analysis of an African-specific variant in the FP2 cis-acting regulatory element

THE CARDIOVASCULAR SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR, RO4607381/JTT-705: PHASE II FINDINGS

176 ANTI-INFLAMMATORY EFFECTS OF A NOVEL INDUCER OF APOLIPOPROTEIN A-I SYNTHESIS: INSIGHTS FROM THE ASSERT STUDY

196 INCREASING CIRCULATING CONCENTRATION OF ALL HDL PARTICLE SUBCLASSES IN HYPER-RESPONDERS TO APOLIPOPROTEIN A-I INDUCTION: INSIGHTS FROM THE ASSERT STUDY

MS351 FOLLOW-UP OF CHILDREN AFTER POSITIVE GENETIC TESTING IN THE DUTCH NATIONAL SCREENING PROGRAM FOR FAMILIAL HYPERCHOLESTEROLEMIA

66 THE MOLECULAR BASIS OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA: ASSESSMENT IN A LARGE COHORT OF HYPERCHOLESTEROLEMIC CHILDREN

COMPARISON OF EFFECTS OF TORCETRAPIB AND RO4607381/JTT-705 ON BLOOD PRESSURE AND TISSUE EXPRESSION OF RENIN-ANGIOTENSIN SYSTEM-RELATED GENES IN RATS

PO23-733 INTENSIVE ATORVASTATIN THERAPY IS ASSOCIATED WITH SIGNIFICANT CARDIOVASCULAR BENEFITS IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE: THE TNT STUDY

LB-OR-3 RELATIONSHIP BETWEEN HIGH-DENSITY LIPOPROTEIN PARTICLE SIZE AND CORONARY ARTERY DISEASE RISK IN THE EPIC-NORFOLK PROSPECTIVE STUDY

Suchergebnisse filtern